Mostrar el registro sencillo del ítem

Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons

dc.contributor.authordel Amo, Julia
dc.contributor.authorPolo, Rosa
dc.contributor.authorMoreno, Santiago
dc.contributor.authorDíaz, Asunción
dc.contributor.authorMartínez, Esteban
dc.contributor.authorArribas, José Ramón
dc.contributor.authorJarrín, Inma
dc.contributor.authorHernán, Miguel A.
dc.contributor.otherAntela López, Antonioes
dc.contributor.otherLosada Arias, Elenaes
dc.contributor.otherMariño Callejo, Ana Isabeles
dc.contributor.otherMena de Cea, Alvaroes
dc.contributor.otherOcampo Hermida, Antonioes
dc.contributor.otherPousada Fernández, Guillermoes
dc.contributor.otherValcarce Pardeiro, Nieveses
dc.date.accessioned2021-11-18T09:01:22Z
dc.date.available2021-11-18T09:01:22Z
dc.date.issued2020
dc.identifier.issn1044-3983
dc.identifier.otherhttps://pubmed.ncbi.nlm.nih.gov/32773469/es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15661
dc.description.abstractThe risk of COVID-19 diagnosis and hospitalization among HIV-positive individuals is lower in those receiving treatment with TDF/FTC than in those receiving other ART regimes. This association does not seem to be explained by confounding due to unmeasured clinical characteristics. Our finding is compatible with accumulating evidence on a potential effect of TDF/FTC against SARS-CoV-2 infection.en
dc.language.isoenges
dc.subject.meshRisk*
dc.subject.meshIntegrase Inhibitors*
dc.subject.meshCooperative Behavior*
dc.subject.meshHIV*
dc.subject.meshIncidence*
dc.titleAntiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Personses
dc.typeArtigoes
dc.bbddEmbase*
dc.bbddWOK*
dc.contributor.authorcorpThe Spanish HIV/COVID-19 Collaborationes
dc.identifier.doi10.1097/EDE.0000000000001235
dc.identifier.pmid32773469
dc.issue.number6es
dc.journal.titleEpidemiologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Farmaciaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Medicina Internaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Medicina Internaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Medicina Internaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña ::Medicina Internaes
dc.page.initiale49es
dc.page.finale51es
dc.relation.publisherversionhttps://journals.lww.com/epidem/Fulltext/2020/11000/Antiretrovirals_and_Risk_of_COVID_19_Diagnosis_and.21.aspxes
dc.rights.accessRightsopenAccesses
dc.subject.decsVIH*
dc.subject.decsincidencia*
dc.subject.decsconducta cooperativa*
dc.subject.decsriesgo*
dc.subject.decsinhibidores de la integrasa*
dc.subject.keywordCHUFes
dc.subject.keywordCHUSes
dc.subject.keywordCHUVIes
dc.subject.keywordCHUACes
dc.typefidesArtigo de Opinión (Editorial, Carta, ...)es
dc.typesophosArtículo de Opiniónes
dc.volume.number31es


Ficheros en el ítem

Descargar/
Nombre:
Antiretrovirals_Letter.pdf
Tamaño:
109.4Kb
Formato:
PDF
Descripción:
Epidemiology. 2020 Nov;31(6):e49-e51

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem